Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · RELMADA THERAPEUTICS, INC. (RLMD)

Relmada Therapeutics says Chief Medical Officer Raj Pruthi's employment ended September 3, 2026

Neutral Impact 2 of 5 leadership Written later

Relmada Therapeutics disclosed in a Form 8-K that Dr. Raj S. Pruthi's employment as Chief Medical Officer – Urology ended on September 3, 2026. The filing does not state the reason for the departure or name a successor.

Key points

  • Dr. Raj S. Pruthi's employment as Chief Medical Officer – Urology ended on September 3, 2026
  • The filing was dated September 8, 2026 and signed by CEO Sergio Traversa
  • The filing does not give a reason for the departure or name a replacement

The filing

CompanyRELMADA THERAPEUTICS, INC. (RLMD)
Form8-K, current report
Filed with the SECSep 8, 2026, 8:00 AM ET
Accession number0001213900-26-097851

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.